You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20 CD47

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Cancer of the Colon Trial in Marseille (BLOOD AND TUMOR)

Recruiting
  • Cancer of the Colon
  • BLOOD AND TUMOR
  • Marseille, France
    Institut Paoli Calmettes
Jul 12, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

CD20 Positive Non Hodgkin Lymphoma Trial in United States (CPO107)

Recruiting
  • CD20 Positive Non Hodgkin Lymphoma
  • Los Angeles, California
  • +4 more
Aug 9, 2022

Erythema, Rosacea Trial in United States (CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%)

Completed
Has Results
  • Erythema
  • Rosacea
  • CD07805/47 gel 0.5%/CD07805/47 Vehicle
  • azelaic acid gel 15%
  • Evansville, Indiana
  • +3 more
Jul 28, 2022

HBV Reactivation in Anti CD20 Treatment

Active, not recruiting
  • Hepatitis B
    • Afula, Tsafon, Israel
      HaEmek Medical Center
    Mar 14, 2023

    CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

    Recruiting
    • CD20-positive Non-Hodgkin Lymphoma
    • EX103 injection
    • Zhengzhou, Henan, China
    • +3 more
    Aug 28, 2023

    Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Apr 10, 2023

    Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

    Not yet recruiting
    • Nephrotic Syndrome
    • Genova, Italy
      IRCCS G. Gaslini
    Jan 19, 2023

    Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

    Recruiting
    • Relapsing Multiple Sclerosis
    • Ublituximab
    • Fort Collins, Colorado
    • +1 more
    May 26, 2023

    CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

    Recruiting
    • CD20-positive B-cell Non-Hodgkin's Lymphoma
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Apr 6, 2023

    Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

    Not yet recruiting
    • Advanced Solid Tumor
    • +5 more
    • (no location specified)
    Mar 20, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    Health Status of Children Born After Assisted Reproductive

    Recruiting
    • Children Born After Assisted Reproductive Technologies
    • +2 more
    • hemogram examination
    • Almaty, Kazakhstan
      Sevara ilmuratova
    Oct 17, 2023

    P47-Phox, Deficiency of Trial in London (Lentiviral vector transduced CD34+ cells)

    Not yet recruiting
    • P47-Phox, Deficiency of
    • Lentiviral vector transduced CD34+ cells
    • London, United Kingdom
      Great Ormond Street Hospital
    Aug 2, 2022

    CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

    Terminated
    • CD20-positive Non-Hodgkin Lymphoma
    • Rituximab + MG4101
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 24, 2022

    Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

    Recruiting
    • Recurrent Acute Lymphoblastic Leukemia
    • +15 more
    • Anti-CD19/CD20/CD22 CAR T-Cells
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 4, 2022

    Primary Membranous Nephropathy Trial in Beijing (B007)

    Not yet recruiting
    • Primary Membranous Nephropathy
    • Beijing, China
      Peking university first hospital
    Dec 20, 2022

    Patients With Recurrent Acute Myelogenous Leukemia After Transplantation Trial in Suzhou (CD47 mAb)

    Recruiting
    • Patients With Recurrent Acute Myelogenous Leukemia After Transplantation
    • CD47 monoclonal antibody
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University, Jiangsu Ins
    Mar 3, 2022

    Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension Trial in Beijing (Rituximab)

    Not yet recruiting
    • Systemic Lupus Erythematosus
    • Pulmonary Arterial Hypertension
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Apr 13, 2023

    COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

    Active, not recruiting
    • COVID-19
    • +3 more
    • Convalescent Plasma
    • Rochester, Minnesota
      Mayo Clinic
    Jul 15, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
    • +4 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Sep 22, 2022

    Relapsed/Refractory Lymphoma Trial in Beijing (Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection)

    Recruiting
    • Relapsed/Refractory Lymphoma
    • Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciense
    Jan 10, 2022